Concepedia

Author

Emre Altinmakas

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

E. Altinmakas, Emre Altinmakas

13

Publications

480

Citations

6

H-Index

12

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterHarvard UniversityDana-Farber Cancer InstituteBeth Israel Deaconess Medical Center
EA

About

Emre Altinmakas is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

457

2

Cancer Therapeutics

3

3

446

3

Surgical Oncology

2

2

75

4

Health Sciences

1

1

26

5

Clinical Trials

1

1

26

Emre Altinmakas

×

5

Publications

471

Citations

5

H-Index

YearCitations

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir, Eric Jonasch, Laurence Albigès,

European Urology

2015

356

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

Matthew T. Campbell, Mehmet Asım Bilen, Amishi Y. Shah,

European Journal of Cancer

2018

64

Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.

Nizar M. Tannir, Eric Jonasch, Emre Altinmakas,

Journal of Clinical Oncology

2014

26

Clinical Importance of Incidental Homogeneous Renal Masses That Measure 10–40 mm and 21–39 HU at Portal Venous Phase CT: A 12-Institution Retrospective Cohort Study

Michael T. Corwin, Emre Altinmakas, Daniella Asch,

American Journal of Roentgenology

2020

14

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Matthew T. Campbell, Randall E. Millikan, Emre Altinmakas,

Clinical Genitourinary Cancer

2014

11

Page 1